Lynch/Colorectal High Risk Panel
Test code: GDB522
Related gene(s): APC, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2
The Lynch/Colorectal High-Risk Panel analyzes genes associated with lynch syndrome, colorectal cancer, familial adenomatous polyposis (FAP), and attenuated familial adenomatous polyposis (AFAP). Lynch syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is the most common hereditary form of colorectal cancer. The NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Colorectal screening can help healthcare providers and patients make decisions regarding surveillance, prevention, and management of specific cancers associated with Lynch.1-2
- Colorectal Cancer
- Familial Adenomatou Polyposis (FAP)
- Attenuated Familial Adenomatous Polyposis (AFAP)
- Lynch syndrome
- Colorectal or endometrial cancer diagnosed under 50 years of age
- Multiple colon polyps (especially ≥ 20 adenomas) at any age
- Tumor testing which indicates an increased risk for a hereditary cancer syndrome known as Lynch syndrome (e.g. microsatellite instability and/or lack of immunohistochemistry staining for a mismatch repair protein)
- Multiple cancers in one person either of the same origin (such as two separate colorectal cancers) or of different origin (such as colon and endometrial cancer in the same individual)
- Multiple relatives diagnosed with the same or related cancers (such as colon, endometrial, ovarian, urinary tract, gastric) on the same side of the family and spanning multiple generations
- Deletion/duplication analysis
- Next-Gen sequencing
- Preferred: 2-5 mL Blood – Lavender Top Tube
- Alternative: Buccal Swabs, Fibroblasts (separate charge for cell culture may apply)
- CPT code(s):* 81292×1, 81294×1, 81295×1, 81297×1, 81317×1, 81298×1, 81300×1
- Turnaround Time:** 2 weeks
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V2.2021. National Comprehensive Cancer Network, Inc. 2021©. All rights reserved. Accessed,[5/18/2021]. To view the most recent and complete version of the guidelines, go online to NCCN.org.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal V1.2021. National Comprehensive Cancer Network, Inc. 2021©. All rights reserved. Accessed, [5/18/2021]. To view the most recent and complete version of the guidelines, go online to NCCN.org.